Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.69 (market cap $6.04B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.87 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 4.2× Iovance Biotherapeutics Inc. Common Stock's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| IOVA | RPRX | |
|---|---|---|
Market Cap | $6.04B | $25.27B |
Volume | 14,805,993 | 3,671,183 |
Sector | Health | Health |
52-Week High | $14.82 | $63.96 |
52-Week Low | $1.81 | $35.44 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $5.97B | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
